The spring edition of our newsletter, ICU Update, is now available. Click here to view the most recent updates from our chapter on our newsletter page!
Southeast Chapter of the SCCM Bi-monthly Meeting – April 18, 2017
You can view the lecture using the link below. Feel free to share with your colleagues or anyone interested.
Southeast Chapter Awarded SCCM Chapters Alliance Excellence Award!
Congratulations! The Southeast Chapter has been selected as the 2018 recipient of the Chapters Alliance Excellence Award! The award is presented in recognition of the innovated approach to promote development and growth to our chapter.
For more information about the award, please click here.
Southeast Chapter of the SCCM Bi-monthly Meeting – February 9, 2017
You can view the lecture using the link below. Feel free to share with your colleagues or anyone interested.
Southeast Chapter of the SCCM Bi-monthly Meeting – December 1, 2016
You can view the lecture using the link below. Feel free to share with your colleagues or anyone interested.
Southeast Chapter of the SCCM Bi-monthly Meeting – October 13, 2016
You can view the lecture slides using the link below. Feel free to share with your colleagues or anyone interested.
Southeast Chapter of the SCCM Bi-monthly Meeting – August 9, 2016
You can view the lecture slides using the link below. Feel free to share with your colleagues or anyone interested.
Southeast Chapter of the SCCM Bi-monthly Meeting – June 14, 2016
You can view the lecture slides using the link below. Feel free to share with your colleagues or anyone interested.
Southeast Chapter of the SCCM Bi-monthly Meeting – April 25, 2016
You can view the lecture slides using the link below. Feel free to share with your colleagues or anyone interested.
Antimicrobial Stewardship Presentation
Southeast Chapter of the SCCM Bi-monthly Meeting – February 4, 2016
Objectives:
- Explain the scientific rationale supporting the investigation and the approval process for antidotes specific to NOAC.
- Compare the inclusion and exclusion criteria for the ongoing RE-VERSE-AD and ANNEXA-4 clinical trials.
- Present clinical scenarios where NOAC antidotes could be considered for a patient.